期刊文献+

3C整合系统与双C系统强化降糖在2型糖尿病患者中的疗效与安全性比较 被引量:1

Comparison of efficacy and safety of “3C” Integrated System and Double C System in intensive hypoglycemic therapy of patients with type 2 diabetes mellitus
下载PDF
导出
摘要 目的比较3C整合系统(美敦力722胰岛素泵)和双C系统(美敦力712胰岛素泵)治疗2型糖尿病高血糖患者疗效与安全性。方法 2015年1—12月住院的60例2型糖尿病高血糖患者,分别给予3C整合系统(美敦力722胰岛素泵)和双C系统(美敦力712胰岛素泵)治疗,根据血糖监测及并病情变化情况,调整胰岛素泵用量,记录相应指标。结果 1、第2、3日内血糖水平差异有统计学意义(P<0.05),3C整合系统(美敦力722胰岛素泵)的降糖效果明显双C系统(美敦力712胰岛素泵);2、两组治疗后血糖漂移有明显差异(P<0.05),3C整合系统(美敦力722胰岛素泵)治疗血糖控制更平稳。3;两组治疗后第3日早餐前血糖、午餐前血糖、睡前血糖、夜3点血糖比较差异有统计血糖意义(P<0.05);4、治疗后低血糖发生率有明显差异(P<0.05),说明3C整合系统(美敦力722胰岛素泵)治疗低血糖发生率更低。结论 3C整合系统(美敦力722胰岛素泵)能够更快、更平稳、更安全的控制血糖。 Objective To compare the efficacy and safety of "3C" Integrated System (Medtronic 722 insulin pump) and "Double C" System (Medtronie 717 insuhn pump) in treating the patients with type 2 diabetes mellitus. Methods 60 patients with type 2 diabetes meUitus who were hospitalized in our hospital from January to December in 2015 were divided into two groups and were given treatment of "3C" Integrated System (Medtronic 722 insuhn pump) and "Double C" System (Medtronic 717 insulin pump ). According to the changes of blood glucose , we adjusted the dosage of insulin pump and recorded the corresponding indicators. Results There was a statistically significant difference about blood glucose levels within 2nd, 3rd days (P〈0.05) ,3C integrated systems (insulin pumps Medtronie 722) had obvious glucose-lowering curative effect compared with Double-C system (Medtronic insulin pump 712). o Blood glucose in two groups had significant changes after they were treated (P〈O.05), and the 3C integrated system (Medtronic insulin pump 712 ) was more stable. The statistic data of the 3rd day blood glucose: including data before breakfast, before lunch, before bed, 3 o'elack at night between two groups had statistical differences (P〈O.05). The incidence of hypoglycemia also had significant difference after treatment (P〈O.05). 3C integrated systems (insulin pumps Medtronie 722) had lower rate of hypoglycemia. Conclusion "3C" Integrated System (Medtronic 722 insulin pump) can control blood glucose, more stably, more securely and faster.
出处 《新疆医学》 2017年第3期275-278,共4页 Xinjiang Medical Journal
关键词 2型糖尿病 3C整合系统 双C系统 强化降糖 Type 2 diabetes "3C" Integrated System: "Double C" System Intensive hypoglycemic
  • 相关文献

参考文献5

二级参考文献136

  • 1张素华,余路,邱鸿鑫,李晨钟,古泉高,刘隆田,肖谦,粟绍初,李萍,吴应珍.家族性非胰岛素依赖型糖尿病患者的家系调查[J].中华医学杂志,1996,76(6):435-439. 被引量:52
  • 2Brunzetl JD, Robertson RP, Lemer RL, et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests[J]. J Clin Endoerinol Metab, 1976, 42(2): 222-229.
  • 3Heller S, Koenen C, Bode B. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial[J]. Clin Ther, 2009, 31 (10): 2086-2097.
  • 4Hermansen K, Fontaine P, Kukolja KK, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes[J]. Diabetologia, 2004,47(4): 622-629.
  • 5Home P, Bartley P, Russell-Jones D, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial[J]. Diabetes Care, 2004, 27(5): 1081-1087.
  • 6Philis-Tsimikas A, Charpentier G, Clauson P, et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes[J]. Clin Yher, 2006, 28(10); 1569-1581.
  • 7Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes[J]. Diabetes Care, 2006, 29(6): 1269-1274.
  • 8Swinnen SG, Dal.n MP, Aronson R, et al. A 24-week, randomized, treat- to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs[J]. Diabetes Care, 2010, 33(6): 1176-1178.
  • 9Raskin P, Gylvin Y, Weng W, et al. Comparison of insulin detemir and insulin gIargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes[J]. Diabetes Metab Res Rev, 2009, 25(6): 542-548.
  • 10Hollander P, Cooper J, Bregnhoj J, et al. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes[J]. Clin Ther, 2008, 30(11): 1976-1987.

共引文献29

同被引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部